<i>BRCA1</i> Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.

Stefansson, Olafur A; Hilmarsdottir, Holmfridur; Olafsdottir, Kristrun; Tryggvadottir, Laufey; Sverrisdottir, Asgerdur; Johannsson, Oskar T; Jonasson, Jon G; Eyfjord, Jorunn E; Sigurdsson, Stefan

BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.

Stefansson, Olafur A; Hilmarsdottir, Holmfridur; Olafsdottir, Kristrun; Tryggvadottir, Laufey; Sverrisdottir, Asgerdur; Johannsson, Oskar T; Jonasson, Jon G; Eyfjord, Jorunn E; Sigurdsson, Stefan.

Afiliação

Stefansson OA; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Hilmarsdottir H; Cancer Research Laboratory, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Olafsdottir K; Current affiliation deCODE genetics/Amgen Inc., Sturlugata 8, Reykjavik, Iceland.
Tryggvadottir L; Cancer Research Laboratory, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Sverrisdottir A; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Johannsson OT; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Jonasson JG; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
Eyfjord JE; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland.
Sigurdsson S; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland.

JNCI Cancer Spectr ; 4(2): pkz100, 2020 Apr.

Article em En | MEDLINE | ID: mdl-32175521

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google